✦ LIBER ✦

133 Ifosfamide (Holoxan) containing combination chemotherapy of advanced lung cancer-experience from India

✍ Scribed by Behera, D.; Jindal, S.K.; Sharma, S.C.; Gupta, D.

Book ID: 123310093
Publisher: Elsevier Science
Year: 1997
Tongue: English
Weight: 283 KB
Volume: 18
Category: Article
ISSN: 0169-5002
DOI: 10.1016/S0169-5002(97)89412-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Ifosfamide (Holoxan) combination chemoth

Ifosfamide (Holoxan) combination chemotherapy in NSCLC — Experience from India

✍ Behera, D; Aggarwal, A; Sharma, S.C; Gupta, D; Jindal, S.K 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 238 KB

Chemotherapy for small cell lung cancer

Chemotherapy for small cell lung cancer (SCLC) with holoxan (Ifosfamide) containing regimen — Experience from Northern India

✍ Behera, D; Aggarwal, A; Sharma, S.C; Gupta, D; Jindal, S.K 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 103 KB

Combination chemotherapy for extensive s

Combination chemotherapy for extensive small cell lung cancer — experience from India

✍ Behera, D.; Aggarwal, A.N.; Sharma, S.C.; Gupta, D.; Jindal, S.K. 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 45 KB

Ifosfamide, cisplatin, vinblastine combi

Ifosfamide, cisplatin, vinblastine combination chemotherapy in the treatment of advanced non-small-cell lung cancer

✍ Hiroshi Saito; Kaoru Shimokata; Masashi Yamamoto; Hideo Saka; Shuzo Sakai; Hidea 📂 Article 📅 1990 🏛 Springer 🌐 English ⚖ 214 KB

Ifosfamide, cisplatin, vinblastine combi

Ifosfamide, cisplatin, vinblastine combination chemotherapy in the treatment of advanced non-small-cell lung cancer

📂 Article 📅 1991 🏛 Elsevier Science 🌐 English ⚖ 321 KB

A phase I-II study of docetaxel-ifosfami

A phase I-II study of docetaxel-ifosfamide-cisplatin (DIP) combination chemotherapy regimen in advanced nonsmall cell lung cancer

✍ Christos Kosmas; Nicolas B. Tsavaris; Thomas Makatsoris; Adimchi Onyenadum; Mari 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 French ⚖ 96 KB 👁 1 views

## Abstract In an attempt to develop more effective chemotherapy regimens in advanced nonsmall cell lung cancer (NSCLC), we evaluated docetaxel‐ifosfamide‐cisplatin (DIP) based on our previous experience with paclitaxel‐ifosfamide‐cisplatin. Patients with advanced NSCLC (stages III‐IV), WHO‐PS≤2, n